JP2021515775A5 - - Google Patents
Info
- Publication number
- JP2021515775A5 JP2021515775A5 JP2020547008A JP2020547008A JP2021515775A5 JP 2021515775 A5 JP2021515775 A5 JP 2021515775A5 JP 2020547008 A JP2020547008 A JP 2020547008A JP 2020547008 A JP2020547008 A JP 2020547008A JP 2021515775 A5 JP2021515775 A5 JP 2021515775A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- optionally substituted
- group
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023170366A JP2023165998A (ja) | 2018-03-09 | 2023-09-29 | 優先投与される免疫増強薬 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862641003P | 2018-03-09 | 2018-03-09 | |
| US62/641,003 | 2018-03-09 | ||
| US201862700548P | 2018-07-19 | 2018-07-19 | |
| US62/700,548 | 2018-07-19 | ||
| PCT/US2019/021300 WO2019173682A1 (en) | 2018-03-09 | 2019-03-08 | Parenterally administered immune enhancing drugs |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023170366A Division JP2023165998A (ja) | 2018-03-09 | 2023-09-29 | 優先投与される免疫増強薬 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021515775A JP2021515775A (ja) | 2021-06-24 |
| JP2021515775A5 true JP2021515775A5 (enExample) | 2022-03-16 |
| JP7417530B2 JP7417530B2 (ja) | 2024-01-18 |
Family
ID=67846288
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020547008A Active JP7417530B2 (ja) | 2018-03-09 | 2019-03-08 | 優先投与される免疫増強薬 |
| JP2023170366A Withdrawn JP2023165998A (ja) | 2018-03-09 | 2023-09-29 | 優先投与される免疫増強薬 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023170366A Withdrawn JP2023165998A (ja) | 2018-03-09 | 2023-09-29 | 優先投与される免疫増強薬 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US12433836B2 (enExample) |
| EP (1) | EP3761993A4 (enExample) |
| JP (2) | JP7417530B2 (enExample) |
| KR (1) | KR102822181B1 (enExample) |
| CN (1) | CN112004541A (enExample) |
| AU (1) | AU2019231781B2 (enExample) |
| CA (1) | CA3092585A1 (enExample) |
| WO (1) | WO2019173682A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017120508A1 (en) | 2016-01-08 | 2017-07-13 | Arcus Biosciences, Inc. | Modulators of 5'-nucleotidase, ecto and the use thereof |
| MX2021002878A (es) * | 2018-09-11 | 2021-08-16 | Risen Suzhou Pharma Tech Co Ltd | Inhibidores de cd73 y usos farmaceuticos de los mismos. |
| US11530234B2 (en) | 2018-09-11 | 2022-12-20 | Risen (Suzhou) Pharma Tech Co., Ltd. | CD73 inhibitors and pharmaceutical uses thereof |
| EP3893891A4 (en) | 2018-12-13 | 2022-08-03 | Arcus Biosciences, Inc. | SOLID FORMS OF A CD73 INHIBITOR AND THEIR USE |
| CN113795267A (zh) | 2019-03-12 | 2021-12-14 | 艾库斯生物科学有限公司 | 致癌基因驱动的癌症的治疗 |
| WO2020205527A1 (en) | 2019-03-29 | 2020-10-08 | Arcus Biosciences, Inc. | Treatment of cancer utilizing an identified adenosine fingerprint |
| TWI821559B (zh) * | 2019-04-28 | 2023-11-11 | 大陸商上海和譽生物醫藥科技有限公司 | 一種cd73抑制劑，其製備方法和應用 |
| TW202131932A (zh) * | 2019-11-05 | 2021-09-01 | 美商博奥阿迪斯有限公司 | 作為cd73抑制劑的化合物 |
| CA3168923A1 (en) * | 2020-01-30 | 2021-08-05 | ONA Therapeutics S.L. | Combination therapy for treatment of cancer and cancer metastasis |
| KR20250133471A (ko) | 2020-02-18 | 2025-09-05 | 길리애드 사이언시즈, 인코포레이티드 | 항바이러스 화합물 |
| TWI775313B (zh) | 2020-02-18 | 2022-08-21 | 美商基利科學股份有限公司 | 抗病毒化合物 |
| TWI883391B (zh) | 2020-02-18 | 2025-05-11 | 美商基利科學股份有限公司 | 抗病毒化合物 |
| US11633416B1 (en) | 2020-03-06 | 2023-04-25 | Arcus Biosciences, Inc. | Oral formulations of CD73 compounds |
| KR20230026312A (ko) * | 2020-06-17 | 2023-02-24 | 아르커스 바이오사이언시즈 인코포레이티드 | Cd73 억제제의 결정형 및 이의 용도 |
| CA3216162A1 (en) | 2021-04-16 | 2022-10-20 | Gilead Sciences, Inc. | Methods of preparing carbanucleosides using amides |
| EP4353732A1 (en) * | 2021-05-11 | 2024-04-17 | Xizang Haisco Pharmaceutical Co., Ltd. | Small molecular cd73 antagonist and use thereof |
| AU2022328698B2 (en) | 2021-08-18 | 2025-02-20 | Gilead Sciences, Inc. | Phospholipid compounds and methods of making and using the same |
| EP4422643A4 (en) | 2021-10-26 | 2025-11-26 | Southern Res Inst | DEVELOPMENT OF NEW CLOFARABINE ANALOGUES FOR CANCER THERAPY |
| JP2025520300A (ja) * | 2022-06-17 | 2025-07-03 | 上海森輝医薬有限公司 | シクロペンチルアデノシン誘導体及びその医薬的使用 |
| US20240180947A1 (en) * | 2022-10-20 | 2024-06-06 | Arcus Biosciences, Inc. | Lyophilized formulations of cd73 compounds |
| CN117924394A (zh) * | 2023-09-05 | 2024-04-26 | 厦门大学 | 核苷酸类化合物及其制备方法和应用、核素靶向探针及其制备方法和应用、药物组合物 |
| CN117562915A (zh) * | 2023-12-05 | 2024-02-20 | 中国药科大学 | 一种腺苷衍生物在制备预防、缓解或治疗纤维化疾病的药物中的应用 |
| CN120285176A (zh) * | 2025-04-25 | 2025-07-11 | 谈高 | 抗CD73单抗联合Adora1抑制剂在治疗肠纤维化中的应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5569650A (en) * | 1993-06-11 | 1996-10-29 | Sloan-Kettering Institute For Cancer Research | C-nucleoside isosters of analogs thereof and pharmaceutical compositions |
| JP2003535038A (ja) * | 1999-12-30 | 2003-11-25 | スージェン・インコーポレーテッド | 蛋白質キナーゼ活性の調節および癌化学療法において用いるための３−ヘテロアリーリデニル−２−インドリノン化合物 |
| US9090697B2 (en) | 2013-03-15 | 2015-07-28 | Bayer Healthcare Llc | Methods for treating bleeding disorders |
| MA39986A (fr) * | 2014-04-25 | 2017-03-01 | Vitae Pharmaceuticals Inc | Dérivés de purine en tant qu'inhibiteurs de cd73 pour le traitement du cancer |
| WO2017120508A1 (en) * | 2016-01-08 | 2017-07-13 | Arcus Biosciences, Inc. | Modulators of 5'-nucleotidase, ecto and the use thereof |
| EP3423494A1 (en) * | 2016-03-04 | 2019-01-09 | Bristol-Myers Squibb Company | Combination therapy with anti-cd73 antibodies |
| WO2018047139A1 (en) * | 2016-09-12 | 2018-03-15 | Aurigene Discovery Technologies Limited | Compounds as modulators of tigit signalling pathway |
| EP3518934A4 (en) | 2016-10-03 | 2020-06-24 | Arcus Biosciences, Inc. | Inhibitors of adenosine 5'-nucleotidase |
| WO2018094148A1 (en) | 2016-11-18 | 2018-05-24 | Arcus Biosciences, Inc. | Inhibitors of cd73-mediated immunosuppression |
| TW202012637A (zh) * | 2018-04-24 | 2020-04-01 | 瑞典商阿斯特捷利康公司 | 治療癌症之方法 |
| EP3893891A4 (en) * | 2018-12-13 | 2022-08-03 | Arcus Biosciences, Inc. | SOLID FORMS OF A CD73 INHIBITOR AND THEIR USE |
-
2019
- 2019-03-08 CN CN201980018034.4A patent/CN112004541A/zh active Pending
- 2019-03-08 WO PCT/US2019/021300 patent/WO2019173682A1/en not_active Ceased
- 2019-03-08 KR KR1020207028869A patent/KR102822181B1/ko active Active
- 2019-03-08 CA CA3092585A patent/CA3092585A1/en active Pending
- 2019-03-08 EP EP19764884.3A patent/EP3761993A4/en active Pending
- 2019-03-08 AU AU2019231781A patent/AU2019231781B2/en active Active
- 2019-03-08 JP JP2020547008A patent/JP7417530B2/ja active Active
- 2019-03-08 US US16/978,920 patent/US12433836B2/en active Active
-
2023
- 2023-09-29 JP JP2023170366A patent/JP2023165998A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021515775A5 (enExample) | ||
| JP2022020003A5 (enExample) | ||
| JP2025160317A5 (enExample) | ||
| ES2981830T3 (es) | Uso de riluzol, profármacos de riluzol o análogos de riluzol con inmunoterapias para tratar cánceres | |
| JP2019518741A5 (enExample) | ||
| IL275333B2 (en) | Inhibitors of fibroblast activation protein | |
| JP2022507474A5 (enExample) | ||
| JP2020508310A5 (enExample) | ||
| JP2023546010A5 (enExample) | ||
| KR20180105685A (ko) | 투카레솔 또는 이의 유사체를 함유하는 조성물 | |
| EP3385257A1 (en) | 1,3,4-oxadiazole and 1,3,4-thiadiazole derivatives as immunomodulators | |
| US20230165859A1 (en) | N-substituted indole derivatives | |
| ES2946472T3 (es) | Agente antitumoral y potenciador del efecto antitumoral | |
| US20250281514A1 (en) | Treatment of cancer patients having kras mutations | |
| JP2008506710A5 (enExample) | ||
| EA038323B1 (ru) | Комбинация из дексаметазона и edo-s101 для лечения гематологического рака | |
| CN114728994A (zh) | 芳基磷氧类化合物及其用途 | |
| US10829495B2 (en) | Thieno-pyrimidine derivatives and uses thereof | |
| KR102446655B1 (ko) | 면역항암 보조제 | |
| TW201811323A (zh) | 抗腫瘤劑、抗腫瘤效果增強劑及抗腫瘤用套組 | |
| ES2440799T3 (es) | Métodos para tratar cáncer resistente a los fármacos | |
| US20230330081A1 (en) | Pharmaceutical composition for treating tumors | |
| US20180318295A1 (en) | Pharmaceutical composition for cancer immunotherapy and/or immunological activation containing diamino heterocyclic carboxamide compound as active ingredient | |
| US20160128988A1 (en) | Combinations for the treatment of cancer comprising a mps-1 kinase inhibitor and a mitotic inhibitor | |
| RU2004135307A (ru) | Производное эпотилона для лечения гепатомы и других раковых заболеваний |